BELLUS Health Inc. (BLU.TO)
| Previous Close | 7.53 |
| Open | 7.56 |
| Bid | 7.42 x 0 |
| Ask | 7.45 x 0 |
| Day's Range | 7.32 - 7.56 |
| 52 Week Range | 3.01 - 9.31 |
| Volume | 54,826 |
| Avg. Volume | 136,848 |
| Market Cap | 583.614M |
| Beta (5Y Monthly) | -0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
SponsorsOne Secures Distributors in Illinois to Supply the US Midwest
The expansion of our national distribution continues adding the Midwest to Western, Southwest, Southeast, and Northeastern existing distribution partnersWATERLOO, ON / ACCESSWIRE / September 27, 2021 / SponsorsOne Inc.Myles Bartholomew, CEO of SponsorsOne, said: "We continue to build our national distribution channel for our Ready to Drink products and Premium Spirits, ensuring we can service both local and national retailers across the US.
- Business Wire
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
LAVAL, Quebec, September 23, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough ("RCC") and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic prur
- Business Wire
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
LAVAL, Quebec, September 13, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cou
